Drugs / CD19-BCMA CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06947460 | Apr 2025 → Jul 2026 overdue | Sjogren syndrome, lupus nephritis, systemic sclerosis | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06350110 | Jul 2024 → Dec 2025 overdue | Sjogren syndrome, granulomatosis with polyangiitis, idiopathic inflammatory myopathy, lupus nephritis +3 | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19- BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06350110 ↗ |
| Action | Deplete | “CD19-BCMA CAR-T cells offer a potential solution by eradicating the abnormal B cells responsible for antibody production.” NCT06350110 ↗ |
| Modality | Cell therapy | “CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells” NCT06350110 ↗ |
| Route | Intravenous | “CD19/BCMA-CAR T cells intravenously (IV) over a duration of 10-20 minutes” NCT06350110 ↗ |
| Target | CD19 | “Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)” NCT06350110 ↗ |